![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PREDIX INKS POTENTIAL $300M DEAL WITH AMGEN
PREDIX INKS POTENTIAL $300M DEAL WITH AMGEN
July 31, 2006
Predix Pharmaceuticals Inc. has inked a development deal with biotechnology giant Amgen Inc. worth more than $300 million assuming certain milestones are met. The Lexington, Mass., company announced on Monday that it had agreed to
an exclusive collaboration and licensing deal with California-based Amgen.
Boston
Business Journal
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct